XML 51 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
ALLIANCES(Tables)
 12 Months Ended
Dec. 31, 2017
Alliances Statement [Line Items]  
Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]
Selected financial information pertaining to our alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.
 
Year Ended December 31,
Dollars in Millions
2017
 
2016
 
2015
Revenues from alliances:
 
 
 
 
 
Net product sales
$
6,949

 
$
5,568

 
$
4,308

Alliance revenues
1,294

 
1,629

 
2,408

Total Revenues
$
8,243

 
$
7,197

 
$
6,716

 
 
 
 
 
 
Payments to/(from) alliance partners:
 
 
 
 
 
Cost of products sold
$
2,723

 
$
2,129

 
$
1,655

Marketing, selling and administrative
(58
)
 
(28
)
 
15

Research and development
2

 
56

 
693

Other income (net)
(731
)
 
(1,009
)
 
(733
)
 
 
 
 
 
 
Noncontrolling interest, pretax
12

 
16

 
51

Selected Alliance Balance Sheet Information:
 
December 31,
Dollars in Millions
 
2017
 
2016
Receivables – from alliance partners
 
$
522

 
$
903

Accounts payable – to alliance partners
 
878

 
555

Deferred income from alliances(a)
 
467

 
1,194

(a)
Includes unamortized upfront, milestone and other licensing proceeds, revenue deferrals attributed to Atripla* and undelivered elements of diabetes business divestiture proceeds. Amortization of deferred income (primarily related to alliances) was $83 million in 2017, $244 million in 2016 and $307 million in 2015.
Pfizer [Member]  
Alliances Statement [Line Items]  
Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]
Summarized financial information related to this alliance was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2017
 
2016
 
2015
Revenues from Pfizer alliance:
 
 
 
 
 
 
Net product sales
 
$
4,808

 
$
3,306

 
$
1,849

Alliance revenues
 
64

 
37

 
11

Total Revenues
 
$
4,872

 
$
3,343

 
$
1,860

 
 
 
 
 
 
 
Payments to/(from) Pfizer:
 
 
 
 
 
 
Cost of products sold – Profit sharing
 
$
2,314

 
$
1,595

 
$
895

Other income (net) – Amortization of deferred income
 
(55
)
 
(55
)
 
(55
)
Selected Alliance Balance Sheet Information:
 
December 31,
Dollars in Millions
 
2017
 
2016
Deferred income
 
$
466

 
$
521
Gilead [Member]  
Alliances Statement [Line Items]  
Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]
Summarized financial information related to this alliance was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2017
 
2016
 
2015
Revenues from Gilead alliances:
 
 
 
 
 
 
Alliance revenues
 
$
623

 
$
934

 
$
1,096

 
 
 
 
 
 
 
Equity in net loss of affiliates
 
$
13

 
$
12

 
$
17

Selected Alliance Balance Sheet Information:
 
December 31,
Dollars in Millions
 
2017
 
2016
Deferred income
 
$
—

 
$
634
Otsuka [Member]  
Alliances Statement [Line Items]  
Schedule Of Percentage Of Net Sales Payable As Collaboration Fee [Table Text Block]
A fee is paid to Otsuka based on the following percentages of combined annual net sales of Sprycel and Ixempra* in the Oncology Territory (including post divestiture Ixempra* sales) through 2020:
 
% of Net Sales
$0 to $400 million
65%
$400 million to $600 million
12%
$600 million to $800 million
3%
$800 million to $1.0 billion
2%
In excess of $1.0 billion
1%
Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]
Summarized financial information related to this alliance was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2017
 
2016
 
2015
Revenues from Otsuka alliances:
 
 
 
 
 
 
Net product sales
 
$
1,814

 
$
1,670

 
$
1,501

Alliance revenues
 
7

 
2

 
604

Total Revenues
 
$
1,821

 
$
1,672

 
$
2,105

 
 
 
 
 
 
 
Payments to/(from) Otsuka:
 
 
 
 
 
 
Cost of products sold:
 
 
 
 
 
 
Oncology fee
 
$
299

 
$
304

 
$
299

Royalties
 
11

 
10

 
30

Cost of product supply
 
31

 
30

 
35
Lilly [Member]  
Alliances Statement [Line Items]  
Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]
Summarized financial information related to this alliance was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2017
 
2016
 
2015
Revenues from Lilly alliance:
 
 
 
 
 
 
Net product sales
 
$
—

 
$
—

 
$
492

Alliance revenues
 
—

 
—

 
9

Total revenues
 
$
—

 
$
—

 
$
501

 
 
 
 
 
 
 
Cost of products sold
 
$
—

 
$
—

 
$
261

 
 
 
 
 
 
 
Other income (net):
 
 
 
 
 
 
Royalties
 
(224
)
 
(246
)
 
(70
)
Divestiture loss
 
—

 
—

 
171
AstraZeneca [Member]  
Alliances Statement [Line Items]  
Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]
Summarized financial information related to the AstraZeneca alliances was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2017
 
2016
 
2015
Revenues from AstraZeneca alliances:
 
 
 
 
 
 
Net product sales
 
$
6

 
$
—

 
$
14

Alliance revenues
 
125

 
129

 
182

Total Revenues
 
$
131

 
$
129

 
$
196

 
 
 
 
 
 
 
Other income (net):
 
 
 
 
 
 
Amortization of deferred income
 
—

 
(113
)
 
(105
)
Royalties
 
(228
)
 
(227
)
 
(215
)
Transitional services
 
(12
)
 
(7
)
 
(12
)
Divestiture gain
 
(126
)
 
—

 
(82
)
 
 
 
 
 
 
 
Selected Alliance Cash Flow Information:
 
 
 
 
 
 
Deferred income
 
—

 
19

 
34

Divestiture and other proceeds
 
302

 
216

 
374

Selected Alliance Balance Sheet Information:
 
December 31,
Dollars in Millions
 
2017
 
2016
Deferred income – Services not yet performed for AstraZeneca
 
$
—

 
$
38
Schedule Of Royalty Rates Based On Net Sales [Table Text Block]
Royalty rates on net sales are as follows:
 
2015
2016
2017
2018
2019
2020
2021 - 2025
Onglyza* and Farxiga* Worldwide Net Sales up to $500 million
35
%
27
%
12
%
20
%
22
%
25
%
14
%
-
20
%
Onglyza* and Farxiga* Worldwide Net Sales over $500 million
7
%
9
%
12
%
20
%
22
%
25
%
14
%
-
20
%
Amylin products U.S. Net Sales
2
%
2
%
5
%
10
%
12
%
12
%
5
%
-
10
%
Sanofi [Member]  
Alliances Statement [Line Items]  
Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]
Summarized financial information related to this alliance was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2017
 
2016
 
2015
Revenues from Sanofi alliances:
 
 
 
 
 
 
Net product sales
 
$
27

 
$
38

 
$
110

Alliance revenues
 
207

 
200

 
296

Total Revenues
 
$
234

 
$
238

 
$
406

 
 
 
 
 
 
 
Payments to/(from) Sanofi:
 
 
 
 
 
 
Equity in net income of affiliates
 
(95
)
 
(95
)
 
(104
)
Noncontrolling interest – pretax
 
12

 
16

 
51
Sanofi [Member] | Territory Covering Europe and Asia [Member]  
Alliances Statement [Line Items]  
Equity Method Investments Disclosure [Table Text Block]
The following is summarized financial information for interests in the partnerships with Sanofi for the territory covering Europe and Asia, which are not consolidated but are accounted for using the equity method:
 
 
Year Ended December 31,
Dollars in Millions
 
2017
 
2016
 
2015
Net sales
 
$
231

 
$
235

 
$
257

Gross profit
 
192

 
195

 
213

Net income
 
189

 
192

 
209
Ono [Member]  
Alliances Statement [Line Items]  
Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]
Summarized financial information related to this alliance was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2017
 
2016
 
2015
Revenues from Ono alliances:
 
 
 
 
 
 
Net product sales
 
$
145

 
$
147

 
$
113

Alliance revenues
 
268

 
280

 
61

Total Revenues
 
$
413

 
$
427

 
$
174
AbbVie [Member]  
Alliances Statement [Line Items]  
Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]
Summarized financial information related to this alliance was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2017
 
2016
 
2015
Revenues from AbbVie alliance:
 
 
 
 
 
 
Net product sales
 
$
150

 
$
132

 
$
3

 
 
 
 
 
 
 
Payments to/(from) AbbVie:
 
 
 
 
 
 
Cost of products sold – Profit sharing
 
$
41

 
$
34

 
$
1
Reckitt Benckiser Group [Member]  
Alliances Statement [Line Items]  
Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]
Summarized financial information related to this alliance was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2016
 
2015
Revenues from Reckitt alliance:
 
 
 
 
Alliance revenues
 
$
48

 
$
140

 
 
 
 
 
Other income (net) – Divestiture gain
 
(277
)
 
—

 
 
 
 
 
Selected Alliance Cash Flow Information:
 
 
 
 
Other changes in operating assets and liabilities
 
$
—

 
$
(129
)
Divestiture and other proceeds
 
317

 
—